Recombinant Cynomolgus Monkey IL-12 (linked heterodimer), CF

Recombinant Cynomolgus Monkey IL-12 (Catalog # 10215-CL) enhances IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED50 for this effect is 0.15-0.9 ng/mL.

2 μg/lane of Recombinant Cynomolgus Monkey IL-12 (10215-CL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 65-78 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey IL-12 (linked heterodimer), CF Summary

• Additional Information: GS Linker, Defined heterodimer stoichiometry.
• Details of Functionality: Measured by its ability to enhance IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED₅₀ for this effect is 0.15-0.9 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey IL-12 protein
  

  Cynomolgus Monkey IL-12p40 (Ile23-Ser328) Accession # NP_001274204	GGGSGGGSGGGS	Cynomolgus Monkey IL-12p35 (Arg57-Ser253) Accession # XP_005546300
  N-terminus		C-terminus

• Accession #: NP_001274204 (IL-12p40) & XP_005546300 (IL-12p35)
• N-terminal Sequence: Ile23
• Structure / Form: Disulfide-linked heterodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 58 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 65-78 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey IL-12 (linked heterodimer), CF

• CLMF p35
• CLMF1
• Cytotoxic lymphocyte maturation factor 35 kDa subunit
• IL-12 subunit p35
• IL12
• IL-12
• IL-12, subunit p35
• IL12A
• interleukin 12, p35
• interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocytematuration factor 1, p35)
• interleukin-12 alpha chain
• interleukin-12 subunit alpha
• natural killer cell stimulatory factor 1, 35 kD subunit
• NF cell stimulatory factor chain 1
• NK cell stimulatory factor chain 1
• NKSF1
• p35

Background

Interleukin 12, also known as Natural Killer Cell Stimulatory Factor (NKSF) or Cytotoxic Lymphocyte Maturation Factor (CLMF), is a heterodimeric pleiotropic cytokine made up of a 40 kDa (p40) subunit and a 35 kDa (p35) subunit (1, 2). The cynomolgus monkey p35 subunit shares 93.4% sequence identity with the human homolog, and the p40 subunit shares 96.4% identity with its human homolog. IL-12 is produced by macrophages and B lymphocytes and has been shown to have multiple effects on T cells and Natural Killer (NK) cells. Some of these IL-12 activities include the induction of IFN-gamma and TNF in resting and activated T and NK cells; the enhancement of cytotoxic activity of resting NK and T cells, the stimulation of resting T cell proliferation in the presence of a comitogen; and the enhancement of NK cell proliferation (2, 3). Current evidence indicates that IL-12 is a key mediator of cellular-immunity and induces the differentiation of Th1 cells from precursor T helper cells. Based on its activities, it has been suggested that IL-12 may have therapeutic potential as a vaccine adjuvant that promotes cellular-immunity and as an anti-tumor and anti-viral agent (1-3).

1. Hasegawa, H. et al. (2016) Front. Immunol. 7:479.
2. Schurich, A. et al. (2017) Rheumatology. 57:246.
3. Agarwal, P. (2009). J Immunol. 183:1695.

Bioinformatics

• Uniprot:
  • NP_001274204 (IL-12p40) & XP_005546300 (IL-12p35)()